Cargando…

Broad-spectrum β-lactams in obese non-critically ill patients

OBJECTIVES: Obesity may alter the pharmacokinetics of β-lactams. The goal of this study was to evaluate if and why serum concentrations are inadequate when standard β-lactam regimens are administered to obese, non-critically ill patients. SUBJECTS AND METHODS: During first year, we consecutively inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hites, M, Taccone, F S, Wolff, F, Maillart, E, Beumier, M, Surin, R, Cotton, F, Jacobs, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079925/ https://www.ncbi.nlm.nih.gov/pubmed/24956136 http://dx.doi.org/10.1038/nutd.2014.15

Ejemplares similares

B-lactams serum concentrations in critically ill cirrhotic patients: a matched-control study
por: Lheureux, O, et al.
Publicado: (2015)

β-lactam antibiotic concentrations during continuous renal replacement therapy
por: Beumier, Marjorie, et al.
Publicado: (2014)

β-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance
por: Jacobs, Alexandra, et al.
Publicado: (2018)

Therapeutic Drug Monitoring of Antimicrobials in Critically Ill Obese Patients
por: Gorham, Julie, et al.
Publicado: (2023)

Structural basis of broad-spectrum β-lactam resistance in Staphylococcus aureus
por: Alexander, J. Andrew N., et al.
Publicado: (2023)

Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy
por: Seyler, Lucie, et al.
Publicado: (2011)

Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review
por: Gorham, Julie, et al.
Publicado: (2022)

A high aminoglycoside regimen associated with renal replacement therapy for the treatment of multi-drug resistant pathogens
por: Brasseur, A, et al.
Publicado: (2015)

Prediction of Insufficient Beta-Lactam Concentrations in Extracorporeal Membranous Oxygenation Patients
por: Polain, Amandine, et al.
Publicado: (2021)

Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams
por: Gonçalves-Pereira, Joao, et al.
Publicado: (2011)

Hypersensitivity to non-β-lactam antibiotics
por: Merk, Hans F., et al.
Publicado: (2022)

Continuation Versus De-escalation of Broad-Spectrum Antibiotic Therapy in Critically Ill COVID-19 Patients
por: Aldardeer, Namareq F., et al.
Publicado: (2023)

Time Above All Else: Pharmacodynamic Analysis of Β-Lactams in Critically Ill Patients
por: Landmesser, Katherine, et al.
Publicado: (2021)

β-lactam precision dosing in critically ill children: Current state and knowledge gaps
por: Tang Girdwood, Sonya, et al.
Publicado: (2022)

In vitro Susceptibility to β-Lactam Antibiotics and Viability of Neisseria gonorrhoeae Strains Producing Plasmid-Mediated Broad- and Extended-Spectrum β-Lactamases
por: Kandinov, Ilya, et al.
Publicado: (2022)

Altered PBP4 and GdpP functions synergistically mediate MRSA-like high-level, broad-spectrum β-lactam resistance in Staphylococcus aureus
por: Lai, Li-Yin, et al.
Publicado: (2023)

β-Lactams from the Ocean
por: Fisher, Jed F., et al.
Publicado: (2023)

Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation
por: Bakdach, Dana, et al.
Publicado: (2022)

Impact of an Extended Infusion Β-lactam Strategy on Outcomes in Critically Ill Patients with Pseudomonas Infections
por: Klinker, Kenneth, et al.
Publicado: (2017)

A Retrospective, Monocentric Study Comparing Co and Secondary Infections in Critically Ill COVID-19 and Influenza Patients
por: Marcoux, Diane, et al.
Publicado: (2022)

Beta-lactam antibiotics in continuous infusion in critically ill patients
por: Jeurissen, Axel, et al.
Publicado: (2010)

Continuous beta-lactam infusion in critically ill patients: the clinical evidence
por: Abdul-Aziz, Mohd H, et al.
Publicado: (2012)

Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?
por: Barreto, Erin F., et al.
Publicado: (2021)

Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock
por: Taccone, Fabio Silvio, et al.
Publicado: (2010)

Regulation and compartmentalization of β‐lactam biosynthesis
por: Martín, Juan F., et al.
Publicado: (2010)

Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients
por: Han, Ruiying, et al.
Publicado: (2021)

Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae
por: Gibble, Allison M., et al.
Publicado: (2015)

β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value
por: Dilworth, Thomas J., et al.
Publicado: (2022)

318. Beta-lactam Therapeutic Drug Monitoring Improves Attainment of Target Drug Levels in Critically Ill Patients
por: Ausman, Sara, et al.
Publicado: (2023)

In Vitro Susceptibility of Clinical Isolates to Ceftriaxone Alone and Ceftriaxone in Combination With Sulbactam or Tazobactam: A Comparative Study of Broad-Spectrum β-Lactam Antibiotics in India
por: Sanghavi, Sonali, et al.
Publicado: (2023)

Clinical outcome of wild-type AmpC-producing Enterobacterales infection in critically ill patients treated with β-lactams: a prospective multicenter study
por: Mounier, Roman, et al.
Publicado: (2022)

Effect of Obesity on Clinical Failure of Patients Treated With β-Lactams
por: Pinner, Nathan A, et al.
Publicado: (2021)

Preliminary therapeutic drug monitoring data of β-lactams in critically ill patients with SARS-CoV-2 infection
por: Novy, Emmanuel, et al.
Publicado: (2020)

Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?
por: Van Herendael, Bruno, et al.
Publicado: (2012)

Impact of Bicarbonate-β-Lactam Exposures on Methicillin-Resistant Staphylococcus aureus (MRSA) Gene Expression in Bicarbonate-β-Lactam-Responsive vs. Non-Responsive Strains
por: Ersoy, Selvi C., et al.
Publicado: (2021)

1066. Adjuvant β-Lactam Therapy Combined with Vancomycin for Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does β-Lactam class Matter?
por: Dilworth, Thomas J, et al.
Publicado: (2018)

P1554: SYSTEMATIC REVIEW OF EXTENDED VERSUS BOLUS INFUSION OF BROAD-SPECTRUM BETA-LACTAM ANTIBIOTICS FOR FEBRILE NEUTROPENIA
por: Ishikawa, Kazuhiro, et al.
Publicado: (2023)

Therapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with reductions in microbial richness and diversity in persons with cystic fibrosis
por: Hahn, Andrea, et al.
Publicado: (2023)

Reduced Susceptibility to Extended-Spectrum β-Lactams in Vibrio cholerae Isolated in Bangladesh
por: Ceccarelli, Daniela, et al.
Publicado: (2016)

Catalytic Spectrum of the Penicillin-Binding Protein 4 of Pseudomonas aeruginosa, a Nexus for the Induction of β-Lactam Antibiotic Resistance
por: Lee, Mijoon, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_e4rc2u3ifjasgt7ol54oiq1vvb